Listing & Compliance Notices

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(b)(1)(A), 5605(c)(4)).

“February 8, 2023, Allarity Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the resignation of Soren G. Jensen from the Company’s board and audit committee, effective on February 4, 2023, the Company no longer complies with Nasdaq’s independent director and audit committee requirements as set forth in Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) which requires a majority of the board of directors to be comprised of independent directors and an audit committee of at least three independent dire”

Berenson Acquisition Corp. I received a nyse delisting notice notice regarding market value (rules 802.01D).

“February 3, 2023, the New York Stock Exchange (the “NYSE”) notified Berenson Acquisition Corp. I (the “Company”), and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants, each whole warrant exercisable to purchase one share of Class A common stock, par value $0.0001 per share, at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “BACA WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE”

Northern Star Investment Corp. IV received a nyse noncompliance notice notice regarding other (rules 303A.01, 303A.07(a)).

“with financial management expertise. Prior to Ms. Green’s resignation, the Board was comprised of three independent directors and two non-independent directors. As a result of Ms. Green’s resignation, the Board is not currently comprised of a majority of independent directors as required by Section 303A.01 of the NYSE Listed Company Manual. Also as a result of Ms. Green’s resignation, the audit committee does not have at least three members as required by Section 303A.07(a) nor a designated member with financial management expertise as also required by Section 303A.07(a). As required by the NY”

Northern Star Investment Corp. II received a nyse noncompliance notice notice regarding board independence (rules 303A.01, 303A.07(a)).

“February 6, 2023, the Company received an official notice of non-compliance from the NYSE (the “NYSE Notice”). The NYSE Notice stated that the Company will need to correct the non-compliance as promptly as practicable. It is the intention of the Board to appoint two new independent directors as soon as practicable, each duly qualified for service on the audit committee and other committees of the Board, and at least one who can be the designated audit committee member with financial management expertise. The Board is diligently engaged in a search to identify candidates qualified to fill the v”

Applied Molecular Transport Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 8, 2023, Applied Molecular Transport Inc. (the “Company”) received a written notice from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for a period of 30 consecutive business days (the “Notice”). This Notice has no immediate effect on the listing of the Company’s stock on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days f”

Hyzon Motors Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“reviously disclosed, on August 16 and November 16, 2022, the Company received notices from the Nasdaq Listing Qualifications Department notifying the Company that, because the Company had not timely filed the Quarterly Reports with the SEC, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports. After the Company made a submission to the Nasdaq Listing Qualifications Department describing its plan to regain compliance with this rule, the Company was granted an extension until the Extended Date to file the Q”

ESPORTS ENTERTAINMENT GROUP, INC. received a nasdaq extension granted notice regarding other (rules 5550(a)(2), 5550(b)(1)).

“February 8, 2023, Esports Entertainment Group, Inc. (the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) Hearings Panel (“Panel”) notifying the Company that it was granted continued listing of its common stock on the Capital Market tier of the Nasdaq, subject to the Company evidencing compliance with Nasdaq’s minimum bid price and $2.5 million stockholders’ equity requirement, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, on or before March 7, 2023 and March 31, 2023, respectively, and adhering to certain other conditions and requirement”

CEMTREX INC received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 8, 2023, the Company received a notification letter from the Listing Qualifications Department of Nasdaq notifying the Company that it has regained compliance with Listing Rule 5550(a)(2) and is in compliance with all applicable listing standards. The Company’s common stock will continue to be listed and traded on The Nasdaq Stock Market. The hearing scheduled for March 16, 2023 before the Hearings Panel has be cancelled.”

Williams Rowland Acquisition Corp. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“February 7, 2023, the trading in the securities of Williams Rowland Acquisition Corp. (the “Company”) was halted at the close of the market by the New York Stock Exchange (the “NYSE”) due to the Company’s inability to meet the requirements of Section 802.01B of the NYSE’s Listed Company Manual. That Section requires a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly held shares (a “public float”) over a consecutive 30 trading day period of at least $40,000,000. The Company is currently evaluating possible alternatives in ligh”

GRIID Infrastructure Inc. received a nyse delisting notice notice regarding market value.

“February 7, 2023, the New York Stock Exchange (the “NYSE”) notified Adit EdTech Acquisition Corp. (the “Company” or “ADEX”) that trading in the Company’s common stock, units and warrants had been halted, as the Company no longer satisfies the continued listing standard of the NYSE requiring the Company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. The Company has applied to transfer the listing of its securities to the NYSE American LLC (the “NYSE American”), and is workin”

Summit Healthcare Acquisition Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5550(a)(3)).

“February 3, 2023, Summit Healthcare Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which requires the Company to have at least 300 public holders for continued listing on the Nasdaq Capital Market (the “Minimum Public Holders Rule”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the”

Unicycive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(a)(2), 5810(c)(3)(A)).

“February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp”

Unicycive Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp”

Scienture Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity.

“February 6, 2023, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “ Panel ”), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the minimum stockholders’ equity requirement. In the interim, the Company’s common stock will continue to trade on Nasdaq under the symbol “ MEDS ” at least pending the ultimate conclusion of the hearing process. There can be no assurance that the Company’s p”

SYNTEC OPTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding other.

“February 1, 2023, OmniLit Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) indicating that the Company required to maintain a minimum of 1,100,000 publicly held shares (which is equal to total shares outstanding less any shares held by officers, directors, or beneficial owners of 10 percent or more) for continued listing on Nasdaq Global Market and did not comply with Listing Rules. Following receipt of the Notice, the Company promptly responded on February 3, 2023 and informed NASDAQ tha”

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b), 5605(c)(2), 5605(b)(1)(A), 5605(c)(4), 5606(b)).

“February 5, 2023, the Company provided notice to Nasdaq that as a result of Mr. Jensen’s resignation, there are only two independent directors of the Company’s board and audit committee. Under Nasdaq Listing Rule 5605(b), a majority of the board directors must be comprised of independent directors. Under Nasdaq Listing Rule 5605(c)(2), the Company must have an audit committee of three members meeting the criteria of such rule. With Mr. Jensen’s resignation, the Company’s current board consists of four members, two of whom are independent and the Company’s audit committee consist of two members”

Apeiron Capital Investment Corp. received a nyse delisting notice notice regarding market value (rules 802.01B).

“January 31, 2023, Apeiron Capital Investment Corp. ( the “ Company ” ) received a written notice from the staff of the New York Stock Exchange (the “ NYSE ”) stating that the Company was not in compliance with Section 802.01B of the NYSE Listed Company Manual, which requires a listed company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000 (the “ Market Capitalization Requirement ”). The NYSE further advised the Company that, as a result of its failure to comply with the Marke”

Rubius Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5101).

“February 6, 2023, Rubius Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the”

Eargo, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5450(a)(1)).

“February 1, 2023, Eargo received a letter from Nasdaq informing the Company that, because the closing bid price of the Company’s common stock was at least $1.00 per share for the 10 consecutive business days ended January 31, 2023, the Company had regained compliance with Nasdaq Listing Rule 5450(a)(1).”

COFFEE HOLDING CO INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 2, 2023, Coffee Holding Co., Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Annual Report on Form 10-K for the period year October 31, 2022 (the “Annual Report”) with the Securities and Exchange Commission (the “SEC”). The Notice has no immediate effect on the listing or trading of the Company’s common stock”

Peraso Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 1, 2023, Peraso Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on January 31, 2023, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until July 31, 2023, in which to re”

INVACARE HOLDINGS Corp received a nyse delisting notice notice regarding other (rules 802.01D).

“February 1, 2023, the Company was notified by the staff of NYSE Regulation, Inc. (“NYSE Regulation”) that it had suspended trading on the New York Stock Exchange (“NYSE”) and determined to commence proceedings to delist the Company’s common shares, without par value (the “Common Shares”), from the NYSE. NYSE Regulation reached its decision that the Company is no longer suitable for listing pursuant to NYSE Listed Company Manual Section 802.01D after the Company filed a voluntary petition under chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texa”

Marti Technologies, Inc. received a nyse_american deficiency notice notice regarding shareholders (rules 1003(b)(i)(B), 1009).

“February 1, 2023, Galata Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the staff of NYSE Regulation of the New York Stock Exchange (“NYSE”) indicating that the Company is not currently in compliance with Section 1003(b)(i)(B) of the NYSE American LLC (“NYSE American”) Company Guide (the “Company Guide”), which requires the Company to maintain a minimum of 300 public shareholders on a continuous basis. In accordance with Section 1009 of the Company Guide, the Company has been provided with a period of 30 days to respond with a plan advising of actions it has ta”

Spectral AI, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).

“January 22, 2023, Rosecliff Acquisition Corp I (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Listing Rule 5550(a)(4), due to the Company’s failure to meet the minimum 500,000 publicly held shares requirement for the Nasdaq Capital Market. The Notice is only a notification of deficiency, not of imminent delisting. The Notice states that the Company has until March 9, 2023 to submit a plan to achieve and sustain compliance with all Nas”

Kaival Brands Innovations Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“se the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days (December 14, 2022 through January 17, 2023), the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided with a compliance period of 180 calendar days, or until July 31”

Sadot Group Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 31, 2023, Muscle Maker, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the Company’s non-compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) as of January 31, 2023, the Company would need to request a hearing to appeal the determination. The Company will be requesting a hearing before a Nasdaq Hearings Panel (the”

Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 30, 2023, Alzamend Neuro, Inc. (the “Company”) received a notice in the form of a letter (“Deficiency Letter”) from the Listing Qualifications Staff of the Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until July 31, 2023, to regain compliance. The Deficiency Letter states that to regain compliance, the bid price for the”

DIXIE GROUP INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 30, 2023, The Dixie Group, Inc. (the "Company") received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(l). The notification has no immediate effect on the listing of the Company's common stock on Nasdaq. Under the N”

InterPrivate III Financial Partners Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“February 1, 2023 that the NYSE is continuing to evaluate the Company’s application materials submitted and to be submitted by the Company for transitioning the Company’s listing to the NYSE American to determine whether to approve its securities for trading on the NYSE American. The NYSE informed the company that trading of the Company’s Class A common stock, warrants to purchase Class A common stock, and units, each consisting of one share of Class A common stock and one redeemable warrant, would be temporarily halted effective as of approximately 4:00 p.m. Eastern Time on February 2, 2023, t”

FinTech Evolution Acquisition Group received a nyse delisting notice notice regarding minimum bid price (rules 802.01D).

“alue $0.0001 per share (the “Class A Shares”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “FTEV WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company had a right to a review of this determination by a Committee of the Board of Directors of the NYSE. The NYSE applied to the Securities and Exchange Commission to delist the Warrants upon completion of all applicable procedures, including any app”

STRYVE FOODS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“February 1, 2023, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company’s request for a 180-day extension to regain compliance the Bid Price Rule. The Company now has until July 31, 2023 to meet the requirement. If at any time prior to July 31, 2023, the bid price of the Company’s Class A common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule during the additional 180-d”

Dianthus Therapeutics, Inc. /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“January 31, 2023, Magenta Therapeutics, Inc. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutive business day period between December 15, 2022 through January 30, 2023, the Company’s common stock, $0.001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The”

Getaround, Inc received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“January 30, 2023, Getaround, Inc. (the “Company”) received written notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period. The notice has no immediate effect on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE, subject to the Company’s compliance with other NYSE continued listing standards. In accordance with the NYSE Listed Company Manual”

Compute Health Acquisition Corp. received a nyse deficiency notice notice regarding board independence (rules 303A.01).

“January 31, 2023, the Company notified the New York Stock Exchange (the “NYSE”) that, after giving effect to Dr. Alswailem’s resignation, the Company no longer had a majority of independent directors as required by Section 303A.01 of the NYSE Listed Company Manual.”

Metacrine, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 31, 2023, the Company received written notice (the “Delisting Notice”) from Nasdaq notifying the Company that, as a result of its failure to regain compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined that the Company’s common stock will be delisted from the Nasdaq Capital Market. The Delisting Notice indicated that the Company may appeal Nasdaq’s determination pursuant to procedures set forth in Nasdaq Listing Rule 5800 Series. The Company will not appeal this determin”

Scienture Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“January 30, 2023, the Company received a delist determination letter from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension. Specifically, the Company did not complete its proposed transactions and was unable to file a Current Report Form 8-K by the January 25, 2023 deadline previously required by the Staff, evidencing compliance with the Rule. As a result, unless the Company requests an appeal of the Staff’s determination, trading of the Company’s common stock will be suspended at the opening of business on February 8, 2023”

OLB GROUP, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“January 30, 2023, we received a notice from NASDAQ that it had determined that for the prior 10 consecutive business days, from January 12, 2023 to January 27, 2023, the closing bid price for the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2) and the matter is closed. A press release was issued by the Company on February 1, 2023 announcing the determination of compliance. The forgoing description of the Press Release does not purport to be complete and is subject to, and is qualified in its ent”

Parabellum Acquisition Corp. received a nyse delisting notice notice regarding market value (rules 802.01B).

“January 31, 2023, the New York Stock Exchange (the “NYSE”) issued a press release stating that it had determined that Parabellum Acquisition Corp. (“Parabellum”) was not in compliance with Section 802.01B of the NYSE Listed Company Manual requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares of at least $40,000,000, over a consecutive 30 trading day period. The NYSE had determined to commence proceedings to delist from the NYSE Parabellum’s Class A common stock (“Parabellum Common Stock”) and units, each co”

Edible Garden AG Inc received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).

“January 27, 2023, Edible Garden AG Incorporated (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”) which requires the Company to have a minimum of 500,000 publicly held shares. The letter from Nasdaq indicated that according to its calculations, as of January 26, 2023, the date that the Company effected a 30-for-1 reverse split of its common stock, the Company no longer meets the requirements of the Rule. This notice of noncompliance has no immediate impact on th”

Vinco Ventures, Inc. received a nasdaq extension granted notice regarding late filing.

“January 31, 2023, Vinco Ventures, Inc. (the “Company”) received notice of an extension from Nasdaq until February 13, 2023 for the filing of its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2022 and September 30, 2022. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: January 31, 2023 VINCO VENTURES, INC. By: /s/ Brendan Bosack Name: Brendan Bosack Title: CFO”

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 27, 2023, Ensysce Biosciences Inc. (the “Company”) received a notice in the form of a letter (the “Deficiency Letter”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until July 26, 2023, to regain compliance. The Deficiency Letter states that t”

authID Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 25, 2023, authID Inc. (the “Company”) received notice from The Nasdaq Stock Market (“Nasdaq”) that the closing bid price for the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Nasdaq’s notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market. The notice indicates that the Company wil”

Athena Consumer Acquisition Corp. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“January 30, 2023, Athena Consumer Acquisition Corp. (the “Company”) received notifications via phone calls from the staff of the New York Stock Exchange (the “NYSE”) that it has determined that the Company was not in compliance with the requirements of Section 802.01B of the NYSE Listed Company Manual (the “LCM”), which requires a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly held shares (a “public float”) over a consecutive 30 trading day period of at least $40,000,000. The Company has had preliminary discussions with the”

Canna-Global Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

“January 24, 2023, Canna-Global Acquisition Corp (the “ Company ”) received a notice (the “ MVLS Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s listed securities failed to comply with the $50 million market value of listed securities (“ Market Value of Listed Securities ”) requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(2)(A) based upon the Company’s Market Value of Listed Securities for the 30 consecutive business days prior to the date of the MVLS Notice. The Company also received a notice on Jan”

Aries I Acquisition Corp. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“January 24, 2023, Aries I Acquisition Corporation (the “Company”) received a notice from the staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“MVLS”) for the Company’s ordinary shares was below the $35 million minimum MVLS requirement for continued listing on The NASDAQ Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MLVS Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or until July 24, 2023, to regain compliance with”

Advantage Solutions Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)).

“January 25, 2023, Advantage Solutions Inc. (the “Company”) received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2) (“Rule 5605”), which requires, among other things, that the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company (the “Board”) be comprised of a minimum of three independent directors. As previously disclosed on November 23, 2022, Ronald Blaylock, one of the Company’s directors, ceased serving on the Audit Committee as of November 23, 2022, and as a result, the Company’s”

Insight Molecular Diagnostics Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A)(ii)).

“August 9, 2022 indicating that Nasdaq had determined that the Company no longer meets the minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1), as the minimum closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. The Notice provided that the Company may consider applying to transfer the listing of the Company’s common stock to The Nasdaq Capital Market, subject to the Company submitting an online transfer application, paying the requisite fee, satisfying such market’s continued listing requirement for the market value of”

Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 25, 2023 notification to the Company by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”), the Company’s common stock, par value $0.001 (the “Common Stock”), will be delisted from Nasdaq unless the Company requests a hearing before a Nasdaq Hearings Panel (the “Panel”). A copy of the press release is attached as Exhibit 99.1 hereto and incorporated he”

CEMTREX INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“daq notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer met the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). On July 26, 2022, the Company received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC Nasdaq notifying the Company that, it had been granted an additio”

Novo Integrated Sciences, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“January 25, 2023 from Nasdaq advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Rule as a result of its failure to timely file the Form 10-K and its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2022 (the “Form 10-Q”). Per the January Nasdaq Notice and in accordance with the December Nasdaq Notice, the Company has 60 calendar days from receipt of the December Nasdaq Notice or until February 13, 2023, to submit a plan to regain compliance with the Rule with the respect to the Form 10-K and the Form 10-Q. If Nasdaq”